I did not read your entire post since you were incorrect in many points. The drug Genentech started with was called PROTROPIN and is not the same as Nutropin. Get it right if you are going to argue. Genentech had money, just not enough to develop ALL of the great drugs they had in research. Roche had nothing but money. Old products, poor research, and an ancient family that owned the place without a clue how to proceed. Franz Hummer had it right when he said while at Genentech one day, "We can't mess this up". He was the last real leader at Roche with vision. In the US, Roche became a joke and was in the process of dumping people right and left. No new drugs to sell as they were all Genentech products and Roche could not sell them in the US. Can you tell me what was the highest sales Roche had in the US and what was the number before they bought Genentech?
OK, I stand corrected, genentech only a single drug which was HGH but not nutropin; changes nothing, but you made my point; genentech had great ideas, with NO money! On your question about annual sales, the question is silly, since Roche has effectively bankrolled, and owned Genentech since 1990 at the earliest. The real question is at the time of Roche's invest what were Genenetch sales, vs. Roche? Roche was significantly higher.
At the end of the day, it appears to me that you do not know the entire history of GNE. Below is a link to Genentech history on our own website:
http://www.gene.com/about-us/investors/historical-stock-info
As you can see, Roche has pretty much owned us since 1990,we became aNYSE traded company in 1985. So, when did all these great drugs hit the market? Hmm, I think all since 1990 right? Thats right, GNE has been an independent entity of Roche since 1990, read the timeline below and weep! Cant argue with history, my jeans wearing brother. Stop acting like the "divorced surgeon", who "did this all by himself". Roche money and commercial partnership played a massive role in the former entity called GNE, the proof is in the history. You can neither argue with NOR change that!
October 14, 1980
Initial Public Offering (IPO)
1,000,000 shares offered at $35.00
Genentech stock trades on NASDAQ under symbol GENE
March 2, 1988
Genentech stock begins trading on the NYSE under the symbol GNE
September 7, 1990
Genentech and Roche Merger approved by stockholders
Each share of Genentech Common Stock (CUSIP 368 710 109) is exchanged for $18 in cash plus one-half share of Genentech Redeemable Common Stock (CUSIP 368 710 208)
October 25, 1995
Genentech stockholders approve Roche's extended buyout option
Each share of Genentech Redeemable Common Stock (CUSIP 368 710 208) is exchanged for one share of Genentech Callable Putable Common Stock (also known as Genentech Special Common Stock - CUSIP 368 710 307)
June 14, 1999
Roche exercises its Call Option for all outstanding shares of Genentech Special Common Stock - redemption date set for June 30, 1999
June 30, 1999
Genentech redeems its Special Common Stock
Each share of Genentech Special Common Stock (CUSIP 368 710 307) is exchanged for $82.50 in cash (except for those shares held by Roche)
July 19, 1999
Roche sells shares of Genentech Common Stock in a Public Offering
22,000,000 shares offered at $97.00
Genentech stock begins trading on NYSE on July 20, 1999 under the symbol DNA (CUSIP 368 710 406).
October 20, 1999
Roche sells shares of Genentech Common Stock in a Public Offering
20,000,000 shares offered at $143.50; shares begin trading on NYSE on October 21, 1999.
November 2, 1999
Payable date of 2-for-1 stock split
March 26, 2009
Roche acquires all of Genentech Common Stock (CUSIP 368 710 406) at $95 per share. Last day of trading of Genentech Common Stock.
30 years ago Genentech was a tiny company with a single drug called nutropin, which was discovered in someones garage. Genentech had no money and needed a sugar daddy to keep them afloat, so that they could become sort of a research institution rather than a business. 